{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.9","upperLimit":"34.1","value":"17.6"}]}],"title":"25th percentile"},{"categories":[{"measurements":[{"comment":"\"Not applicable\" indicates value cannot be estimated due to censored data.","groupId":"OG000","lowerLimit":"6.9","upperLimit":"NA","value":"34.1"}]}],"title":"Median"},{"categories":[{"measurements":[{"comment":"\"Not applicable\" indicates value cannot be estimated due to censored data.","groupId":"OG000","lowerLimit":"28.5","upperLimit":"NA","value":"NA"}]}],"title":"75th percentile"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Overall survival (OS) defined as the time from first treatment in this study until death from any cause. Data on survival were collected by the site. Time frame was reduced due to early termination of the study. Table reports Kaplan-Meier median with Brookmeyer-Crowley confidence intervals. Number (%) of participants with event: 5 (55.6%) and Number (%) of participants censored: 4 (44.4%).","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants with solid tumors who received anetumab-ravtansine treatment as monotherapy, or in combination with gemcitabine in an applicable Bayer-sponsored anetumab ravtansine study.\n\n8 participants received anetumab ravtansine monotherapy and 1 participant received anetumab ravtansine in combination with gemcitabine. Pooled results were reported.","id":"OG000","title":"Anetumab Ravtansine"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Approximately 3 years (from first study treatment until safety follow-up)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}